Evidence map›Paper›PMID 41820364›Full record

ArticleNature communications2026

Catalytic Proximal Protein Oligomerization as an Anti-Tumor Strategy Targeting WDR5.

Yizheng Fang, Li Jiang, Feifan Wang, Yihui Zhou, Jie Cen, Yuxin Yang, Haiyang Wang, Qi Chen, Yushen Lin, Tingting Wang and 9 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yizheng Fang *Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0003-3235-2417
Li Jiang *Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Feifan WangSchool of Public Health, Zhejiang University School of Medicine, Hangzhou, China.
Yihui ZhouZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Jie CenZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Yuxin YangState Key Laboratory of Extreme Optics and Instrumentation, College of Optical Science and Engineering, Zhejiang University, Hangzhou, China.
Haiyang WangZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Qi ChenZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Yushen LinZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Tingting WangZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Hongxia XuZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Yongping YuZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Chengliang ZhuZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-8285-5795
Qiaojun HeZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
Bo YangZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-6505-2771
Chun ZhouSchool of Public Health, Zhejiang University School of Medicine, Hangzhou, China. chunzhou@zju.edu.cn.ORCID http://orcid.org/0000-0002-9257-468X
Wenteng ChenZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. wentengchen@zju.edu.cn.ORCID http://orcid.org/0000-0001-9366-3679
Longhua TangState Key Laboratory of Extreme Optics and Instrumentation, College of Optical Science and Engineering, Zhejiang University, Hangzhou, China. lhtang@zju.edu.cn.ORCID http://orcid.org/0000-0002-3833-3113
Ji CaoZhejiang Province Key Laboratory of Anti-Cancer Drug Research, Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China. caoji88@zju.edu.cn.ORCID http://orcid.org/0000-0003-2813-6404

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82273943National Natural Science Foundation of China (National Science Foundation of China) 823B2100Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LR22H310002
6 · The paper itself

Abstract

Inducing protein oligomerization holds therapeutic promise, yet identifying or rationally designing effective inducers remains challenging. In this study, we leverage nanopore technology to screen small molecules capable of modulating WD repeat domain 5 (WDR5) protein oligomerization and uncover a oligomerization mechanism which we term Catalytic Proximal Protein Oligomerization (CaPPO). Nanopore sensing enabled rapid identification of WZ-1, a selective WDR5 oligomerization inducer, from our in-house compound library. Biochemical and cryo-EM analyses reveal that WZ-1 binds the WBM site of WDR5 through its 2-aminothiazole moiety, reacts with Cys248 to form an intramolecular disulfide, and, through N-terminal tail-induced proximity of WDR5 molecules, triggers oligomerization via thio-disulfide exchange. Structure-activity relationship studies indicate that the disulfide motif within WZ-1 acts as a molecular scout initiating oligomerization. In cellular assays, WZ-1 exhibits potent anti-tumor activity by disrupting WDR5 interactions at both WIN and WBM sites, leading to transcriptional downregulation of target genes. Collectively, this work not only establishes a nanopore-based screening platform for identifying protein oligomerization inducers, but also validates CaPPO as a promising small-molecule design strategy for therapeutic development.

Indexed as

Antineoplastic AgentsHistone-Lysine N-MethyltransferaseIntracellular Signaling Peptides and ProteinsProtein MultimerizationAnimalsCell Line, TumorDisulfidesHumansNanoporesProtein BindingStructure-Activity RelationshipAntineoplastic AgentsDisulfidesHistone-Lysine N-MethyltransferaseIntracellular Signaling Peptides and ProteinsWDR5 protein, human

Identifiers

PMID41820364
PMCPMC13125440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.